Skip to main content
. 2021 Jun 5;36:100933. doi: 10.1016/j.eclinm.2021.100933

Fig. 3.

Fig. 3

Title: Heart failure hospitalizations were significantly lower in the SGLT2 inhibitor group. Legend: There was a significant 31% relative risk reduction in heart failure hospitalizations among patients with HF treated with SGLT2 inhibitors compared with placebo (OR 0•69; 95% CI 0•62–0•76).